<DOC>
	<DOCNO>NCT02656498</DOCNO>
	<brief_summary>This cross-sectional longitudinal study evaluate clinical utility [ 18F ] THK-5351 positron emission compute tomography cognitively healthy volunteer , mild cognitive impairment ( MCI ) , Alzheimer 's disease ( AD ) neurodegenerative patient .</brief_summary>
	<brief_title>18FTHK-5351 Positron Emission Computed Tomography Study Normal , Mild Cognitive Impairment , Alzheimer 's Disease Other Neurodegenerative Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Mild Cognitive Impairment</mesh_term>
	<mesh_term>Neurodegenerative Diseases</mesh_term>
	<criteria>1 . General Subject Inclusion Criteria In order eligible participation trial , subject must : Be â‰¥ 40 &lt; 80 year age Screening Visit . Be able read 6th grade level equivalent , ( determined investigator , must history academic achievement and/or employment sufficient exclude mental retardation . ) Be able speak , read , hear , understand language trial staff , informed consent form , possess ability respond verbally question , follow instruction , complete questionnaire detail neuropsychological test . Have result clinical laboratory tests/physical examination , vital sign , ECG within normal limit ( 90 day prior [ 18F ] THK5351 positron emission compute tomography ) clinically acceptable investigator screening . Be able possess ability respond verbally question , follow instruction , underwent research assessment , include brain image base investigator 's judgment . Each subject also able willing adhere visit schedule . If female , childbearing potential indicated one follow Each subject ( legal representative ) must sign informed consent form accordance local requirement scope nature investigation explain , screen assessment . Each subject must willing provide blood sample genotyping apolipoprotein E 2 . Cognitively Healthy Subjects 3 . MCI Subjects 4 . AD Subjects 5 . Subjects neurodegenerative disease Exclusion Criteria The subject must exclude participate trial subject fulfil single criterion describe : 1 . General Exclusion Criteria Based investigator ' judgement , patient capable communicate site personnel , patient proficient language psychometric test complete , patient sufficient compliance study procedure . The patient abnormal physical examination abnormal laboratory test result screen clinically significant affect result research , judge investigator . If patient suspicious hypersensitivity allergy [ 18F ] THK5351 derivative . The patient pregnant , attempt become pregnant , nursing ( breastfeed ) child . The patient history alcoholism drug dependency/abuse within last 2 year screen . The patient contraindication undergo positron emission compute tomography MRI , include restrict example : claustrophobia , cardiac pacemaker , metal device around eye spinal cord , cochlear implant , etc . ) screen visit . The patient treat investigational medicinal product ( IMP ) within 30 day prior screen visit . The patient test positive hepatitis B surface antigen ( HBsAg ) , hepatitis C virus antibody ( antiHCV ) , HIV Antibody , syphilis serum test screen visit . The patient receive anticholinergic drug regular basis within 3 month prior screen visit . The patient evidence clinically relevant neurological disorder disease study ( i.e. , prodromal AD ) screening , include limited : territorial cerebral infarction , intracranial hemorrhage , multiple sclerosis , neurosyphilis , mental retardation , hypoxic encephalopathy , major head trauma loss consciousness lead persistent cognitive deficit .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Tau , neurodegeneration , positron emission compute tomography</keyword>
</DOC>